Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BCL6 | P41182 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578649 | 1.00 | EGFR (0.69) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL8314263 | 0.89 | EGFR (0.84) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL8312687 | 0.89 | EGFR (0.75) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL8312684 | 0.89 | EGFR (0.75) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL6993354 | 0.86 | EGFR (0.68) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL7587481 | 0.85 | EGFR (0.77) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL6997215 | 0.85 | EGFR (0.77) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL6997208 | 0.85 | EGFR (0.77) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL8316770 | 0.85 | EGFR (0.77) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL6995190 | 0.85 | EGFR (0.80) | EGFRERBB2HPGDHTTCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | EGFR 1041/4885ERBB2 2419/4885HPGD 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.